An international collaborative study published in Genome Medicine provides a major breakthrough for families and clinicians dealing with unsolved titinopathies.

While it is well established that truncating variants in the titin gene (TTN) cause skeletal and cardiac muscle diseases, interpreting rare TTN missense variants has long been a diagnostic hurdle due to the gene’s massive size and complexity. By examining a global cohort of 30 unsolved myopathy patients carrying a TTN truncating variant alongside a rare missense variant in trans, the research team successfully integrated clinical data, advanced AI predictions (AlphaMissense), and in vitro functional assays.

The study outlines a practical diagnostic framework, demonstrating that specific missense mutations—particularly those altering structural proline and arginine residues—disrupt titin domain folding and trigger harmful protein aggregation. Notably, the findings successfully upgraded two variants, including a widespread European founder mutation, to “likely pathogenic,” offering immediate answers to affected families and establishing a scalable blueprint to improve global diagnostic accuracy in titinopathies.